Gastroparesis Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2021-2026
In gastroparesis Dopamine (D2) receptor is a major focus of drug developers. There are 17 drugs in the pipeline with 90% molecules present in early stage. Mid-sized Pharma dominates R&D in this indication. The rising prevalence and more frequent use of newer symptomatic treatments are expected to drive the market. However, the market growth is limited by delayed diagnosis, frequent usage of over-the-counter medicines, and decreased compliance due to side effects associated with gastroparesis therapies.
This reports provides a data-driven overview of the current and future competitive landscape in gastroparesis therapeutics.
GlobalData’s Gastroparesis Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2021-2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Reasons to Buy
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the gastroparesis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global gastroparesis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Key Findings
- Report Scope
- Disease Overview
- Epidemiology Overview: Diagnosed Prevalence of Gastroparesis in 2021
- Marketed Drugs Assessment
- Marketed Drugs Overview
- Marketed Drug Profile: Evoke Pharma's Gimoti
- Pipeline Drugs Assessment
- Pipeline Overview
- Pipeline Products - Breakdown by Region
- Global Pipeline Products - Target/Mechanism of Action Breakdown
- Global Gastroparesis Pipeline Products - Phase Transition Success Rates
- Global Gastroparesis Pipeline Products - Likelihood of Approval
- Clinical Trials Assessment
- Global Clinical Trials - Overview by Status and Phase
- Clinical Trials - Overview by Region
- Clinical Trials - Therapy Area Perspective
- Global Clinical Trials - Leading Sponsors
- Global Clinical Trials - Enrollment Analytics
- Global Clinical Trials - Enrollment Analytics, Overview by Region
- Global Clinical Trials - Feasibility Analysis: Comparison of Leading Late-Stage Trial Designs
- Clinical Trials - Feasibility Analysis: Geography Overview
- Commercial Assessment
- Commercial Assessment - Upcoming Market Catalysts
- Digital Marketing
- Digital Marketing - Top Branded Websites
- Digital Marketing - Digital Display Advertising Spend
- Digital Marketing - Trust Flow and Citation Flow
- About the Authors
- Contact Us
- Contact Us - A Global Network of Offices